{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:19:41Z","timestamp":1790263181066,"version":"4.1.0"},"reference-count":137,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melatonin is a hormone secreted by the pineal gland under the control of the circadian rhythm, and is released in the dark and suppressed during the day. In the past decades, melatonin has been considered to be used in the treatment for diabetes mellitus (DM). This is due to a functional inter-relationship between melatonin and insulin. Elevated oxidative stress is a feature found in DM associated with diabetic neuropathy (DN), retinopathy (DR), nephropathy and cardiovascular disease. Reactive oxygen species (ROS) and nitrogen oxidative species (NOS) are usually produced in massive amounts via glucose and lipid peroxidation, and this leads to diabetic complications. At the molecular level, ROS causes damage to the biomolecules and triggers apoptosis. Melatonin, as an antioxidant and a free radical scavenger, ameliorates oxidative stress caused by ROS and NOS. Besides that, melatonin administration is proven to bring other anti-DM effects such as reducing cellular apoptosis and promoting the production of antioxidants.<\/jats:p>","DOI":"10.1515\/hmbci-2019-0036","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T04:02:41Z","timestamp":1573012961000},"source":"Crossref","is-referenced-by-count":21,"title":["A new prospective on the role of melatonin in diabetes and its complications"],"prefix":"10.1515","volume":"40","author":[{"given":"Jia Xin","family":"Mok","sequence":"first","affiliation":[{"name":"School of Medical Laboratory Science , University of Otago , Dunedin 9054 , New Zealand"},{"name":"University of Otago , Dunedin School of Medicine, Department of Pathology, Medical Laboratory Science , Dunedin 9016 , New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Hau","family":"Ooi","sequence":"additional","affiliation":[{"name":"International Medical University , School of Health Science , Kuala Lumpur 57000 , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khuen Yen","family":"Ng","sequence":"additional","affiliation":[{"name":"Monash University Malaysia , School of Pharmacy , Selangor 47500 , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhun Yian","family":"Koh","sequence":"additional","affiliation":[{"name":"International Medical University , School of Health Science , Kuala Lumpur 57000 , Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soi Moi","family":"Chye","sequence":"additional","affiliation":[{"name":"International Medical University , School of Health Science , Kuala Lumpur 57000 , Malaysia"},{"name":"School of Health Science, Division of Biomedical Science and Biotechnology , International Medical University , No. 126, Jalan Jalil Perkasa 19, Bukit Jalil , 57000 Kuala Lumpur , Malaysia , Phone: +60-3-27317220, Fax: +06-3-86567229"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2025121207171211691_j_hmbci-2019-0036_ref_001_w2aab3b7b2b1b6b1ab1b7b1Aa","doi-asserted-by":"crossref","unstructured":"You W, Henneberg M. Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ Open Diabetes Res Care. 2016;4:1\u20137.","DOI":"10.1136\/bmjdrc-2015-000161"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_002_w2aab3b7b2b1b6b1ab1b7b2Aa","doi-asserted-by":"crossref","unstructured":"Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world \u2013 a growing challenge. N Engl J Med. 2007;356:213\u20135.1722994810.1056\/NEJMp068177","DOI":"10.1056\/NEJMp068177"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_003_w2aab3b7b2b1b6b1ab1b7b3Aa","doi-asserted-by":"crossref","unstructured":"Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6:87\u2013123.10.3390\/genes601008725774817","DOI":"10.3390\/genes6010087"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_004_w2aab3b7b2b1b6b1ab1b7b4Aa","doi-asserted-by":"crossref","unstructured":"Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11:1185\u2013200.2524978710.7150\/ijms.10001","DOI":"10.7150\/ijms.10001"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_005_w2aab3b7b2b1b6b1ab1b7b5Aa","doi-asserted-by":"crossref","unstructured":"Bondeva T, Wolf G. Reactive oxygen species in diabetic nephropathy: friend or foe\u202f? Nephrol Dial Transplant. 2014;29:1998\u20132003.10.1093\/ndt\/gfu03724589719","DOI":"10.1093\/ndt\/gfu037"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_006_w2aab3b7b2b1b6b1ab1b7b6Aa","doi-asserted-by":"crossref","unstructured":"Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract. 2008;4:285\u201393.10.1038\/ncpendmet0786","DOI":"10.1038\/ncpendmet0786"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_007_w2aab3b7b2b1b6b1ab1b7b7Aa","doi-asserted-by":"crossref","unstructured":"Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2011;46:217\u201324.2111180010.1016\/j.exger.2010.11.007","DOI":"10.1016\/j.exger.2010.11.007"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_008_w2aab3b7b2b1b6b1ab1b7b8Aa","doi-asserted-by":"crossref","unstructured":"Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365\u201373.10.1016\/j.biopha.2005.07.00216081237","DOI":"10.1016\/j.biopha.2005.07.002"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_009_w2aab3b7b2b1b6b1ab1b7b9Aa","doi-asserted-by":"crossref","unstructured":"Mayo JC, Tan D, Sainz RM, Alatorre-jimenez M. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253\u201378.10.1111\/jpi.1236027500468","DOI":"10.1111\/jpi.12360"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_010_w2aab3b7b2b1b6b1ab1b7c10Aa","doi-asserted-by":"crossref","unstructured":"Wang J, Wang H. Oxidative stress in pancreatic beta cell regeneration. Oxid Med Cell Longev. 2017;2017:1930261.28845211","DOI":"10.1155\/2017\/1930261"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_011_w2aab3b7b2b1b6b1ab1b7c11Aa","doi-asserted-by":"crossref","unstructured":"Chattoraj A, Liu T. Melatonin formation in mammals: in vivo perspectives. Rev Endocr Metab Disord. 2009;10:237\u201343.10.1007\/s11154-009-9125-520024626","DOI":"10.1007\/s11154-009-9125-5"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_012_w2aab3b7b2b1b6b1ab1b7c12Aa","doi-asserted-by":"crossref","unstructured":"Devavry S, Legros C, Brasseur C, Cohen W, Guenin SP, Delagrange P, et al. Molecular pharmacology of the mouse melatonin receptors MT1and MT2. Eur J Pharmacol. 2012;677:15\u201321.10.1016\/j.ejphar.2011.12.009","DOI":"10.1016\/j.ejphar.2011.12.009"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_013_w2aab3b7b2b1b6b1ab1b7c13Aa","doi-asserted-by":"crossref","unstructured":"McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. J Am Med Assoc. 2013;309:1388\u201396.10.1001\/jama.2013.2710","DOI":"10.1001\/jama.2013.2710"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_014_w2aab3b7b2b1b6b1ab1b7c14Aa","doi-asserted-by":"crossref","unstructured":"Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 1998;78:687\u2013721.10.1152\/physrev.1998.78.3.6879674691","DOI":"10.1152\/physrev.1998.78.3.687"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_015_w2aab3b7b2b1b6b1ab1b7c15Aa","doi-asserted-by":"crossref","unstructured":"Tan HY, Ng KY, Koh RY, Chye SM. Pharmacological effects of melatonin as neuroprotectant in rodent model: a review on the current biological evidence. Cell Mol Neurobiol. 2019.","DOI":"10.1007\/s10571-019-00724-1"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_016_w2aab3b7b2b1b6b1ab1b7c16Aa","doi-asserted-by":"crossref","unstructured":"She M, Laudon M, Yin W. Melatonin receptors in diabetes: a potential new therapeutical target? Eur J Pharmacol. 2015;744:220\u20133.","DOI":"10.1016\/j.ejphar.2014.08.012"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_017_w2aab3b7b2b1b6b1ab1b7c17Aa","doi-asserted-by":"crossref","unstructured":"Mulder H. Melatonin signalling and type 2 diabetes risk: too little, too much or just right? Diabetologia. 2017;60:826\u20139.2830330310.1007\/s00125-017-4249-8","DOI":"10.1007\/s00125-017-4249-8"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_018_w2aab3b7b2b1b6b1ab1b7c18Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, B\u00e4hr I, M\u00fchlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14:6981\u20137015.10.3390\/ijms1404698123535335","DOI":"10.3390\/ijms14046981"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_019_w2aab3b7b2b1b6b1ab1b7c19Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, Bach AG, M\u00fchlbauer E. Parallel signaling pathways of melatonin in the pancreatic \u03b2-cell. J Pineal Res. 2006;40:184\u201391.10.1111\/j.1600-079X.2005.00297.x16441556","DOI":"10.1111\/j.1600-079X.2005.00297.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_020_w2aab3b7b2b1b6b1ab1b7c20Aa","doi-asserted-by":"crossref","unstructured":"La Fleur SE, Kalsbeek A, Wortel J, Van Der Vliet J, Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night- time glucose concentrations. J Neuroendocrinol. 2001;13:1025\u201332.11722698","DOI":"10.1046\/j.1365-2826.2001.00717.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_021_w2aab3b7b2b1b6b1ab1b7c21Aa","doi-asserted-by":"crossref","unstructured":"Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19:1410\u20138.10.1016\/j.drudis.2014.04.01424792719","DOI":"10.1016\/j.drudis.2014.04.014"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_022_w2aab3b7b2b1b6b1ab1b7c22Aa","doi-asserted-by":"crossref","unstructured":"Nagorny CL, Sathanoori R, Voss U, Mulder H, Wierup N. Distribution of melatonin receptors in murine pancreatic islets. J Pineal Res. 2011;50:412\u20137.2135587710.1111\/j.1600-079X.2011.00859.x","DOI":"10.1111\/j.1600-079X.2011.00859.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_023_w2aab3b7b2b1b6b1ab1b7c23Aa","doi-asserted-by":"crossref","unstructured":"Picinato MC, Hirata AE, Cipolla-Neto J, Curi R, Carvalho CR, Anh\u00ea GF, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res. 2008;44:88\u201394.18078453","DOI":"10.1111\/j.1600-079X.2007.00493.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_024_w2aab3b7b2b1b6b1ab1b7c24Aa","unstructured":"Akmali M, Ahmadi R, Vessal M. Pre- and post-treatment of streptozocin administered rats with melatonin: effects on some hepatic enzymes of carbohydrate metabolism. Arch Iran Med. 2010;13:105\u201310.20187663"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_025_w2aab3b7b2b1b6b1ab1b7c25Aa","doi-asserted-by":"crossref","unstructured":"Fonken LK, Nelson RJ. The effects of light at night on circadian clocks and metabolism. Endocr Rev. 2014;35:648\u201370.2467319610.1210\/er.2013-1051","DOI":"10.1210\/er.2013-1051"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_026_w2aab3b7b2b1b6b1ab1b7c26Aa","doi-asserted-by":"crossref","unstructured":"Greenhill C. Risk factors: melatonin signalling implicated in the risk of T2DM. Nat Rev Endocrinol. 2016;12:374.2723094710.1038\/nrendo.2016.85","DOI":"10.1038\/nrendo.2016.85"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_027_w2aab3b7b2b1b6b1ab1b7c27Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40:135\u201343.10.1111\/j.1600-079X.2005.00287.x16441550","DOI":"10.1111\/j.1600-079X.2005.00287.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_028_w2aab3b7b2b1b6b1ab1b7c28Aa","doi-asserted-by":"crossref","unstructured":"Cavalcanti-proenc C, Bouatia-naji N, Sparso T, Rocheleau G, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89\u201394.1906090910.1038\/ng.277","DOI":"10.1038\/ng.277"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_029_w2aab3b7b2b1b6b1ab1b7c29Aa","doi-asserted-by":"crossref","unstructured":"Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol [Internet]. 2019;15:105\u201325.10.1038\/s41574-018-0130-1","DOI":"10.1038\/s41574-018-0130-1"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_030_w2aab3b7b2b1b6b1ab1b7c30Aa","doi-asserted-by":"crossref","unstructured":"Jonsson A, Ladenvall C, Ahluwalia TS, Kravic J, Krus U, Taneera J, et al. Effects of common genetic variants associated with type 2 diabetes and glycemic traits on \u03b1- and \u03b2-cell function and insulin action in humans. Diabetes. 2013;62:2978\u201383.10.2337\/db12-162723557703","DOI":"10.2337\/db12-1627"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_031_w2aab3b7b2b1b6b1ab1b7c31Aa","doi-asserted-by":"crossref","unstructured":"Walford GA, Green T, Neale B, Isakova T, Rotter JI, Grant SF, et al. Common genetic variants differentially influence the transition from clinically defined states of fasting glucose metabolism. Diabetologia. 2012;55:331\u20139.2203852210.1007\/s00125-011-2353-8","DOI":"10.1007\/s00125-011-2353-8"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_032_w2aab3b7b2b1b6b1ab1b7c32Aa","doi-asserted-by":"crossref","unstructured":"Tuomi T, Nagorny CL, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23:1067\u201377.10.1016\/j.cmet.2016.04.00927185156","DOI":"10.1016\/j.cmet.2016.04.009"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_033_w2aab3b7b2b1b6b1ab1b7c33Aa","unstructured":"Gaulton KJ, Ferreira T, Lee Y, Raimondo A, M\u00e4gi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47:1415\u201325.10.1038\/ng.343726551672"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_034_w2aab3b7b2b1b6b1ab1b7c34Aa","doi-asserted-by":"crossref","unstructured":"Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R. Minireview: toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol Endocrinol. 2013;27:1217\u201333.10.1210\/me.2013-110123798576","DOI":"10.1210\/me.2013-1101"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_035_w2aab3b7b2b1b6b1ab1b7c35Aa","unstructured":"Ye\u01e7in ZA, Mutluay R, Elbeg \u015e, Karaku\u015f R, \u00c7akir N. The impact of melatonin on glucose homeostasis. Turkish J Endocrinol Metab. 2009;13:52\u20135."},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_036_w2aab3b7b2b1b6b1ab1b7c36Aa","unstructured":"Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77\u201381.1906090710.1038\/ng.290"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_037_w2aab3b7b2b1b6b1ab1b7c37Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, M\u00fchlbauer E. Melatonin and type 2 diabetes \u2013 a possible link? J Pineal Res. 2007;42:350\u20138.10.1111\/j.1600-079X.2007.00426.x17439551","DOI":"10.1111\/j.1600-079X.2007.00426.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_038_w2aab3b7b2b1b6b1ab1b7c38Aa","doi-asserted-by":"crossref","unstructured":"Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia. 2009;52:1240\u20139.1937788810.1007\/s00125-009-1359-y","DOI":"10.1007\/s00125-009-1359-y"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_039_w2aab3b7b2b1b6b1ab1b7c39Aa","doi-asserted-by":"crossref","unstructured":"Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fern\u00e1ndez-V\u00e1zquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. 2012;52:203\u201310.2188344510.1111\/j.1600-079X.2011.00928.x","DOI":"10.1111\/j.1600-079X.2011.00928.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_040_w2aab3b7b2b1b6b1ab1b7c40Aa","unstructured":"Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J. 2006;27:1483\u20138.17013468"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_041_w2aab3b7b2b1b6b1ab1b7c41Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, Hofmann K, B\u00e4hr I, Streck S, Albrecht E, Wedekind D, et al. The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia. 2011;54:1831\u201340.2149115910.1007\/s00125-011-2138-0","DOI":"10.1007\/s00125-011-2138-0"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_042_w2aab3b7b2b1b6b1ab1b7c42Aa","doi-asserted-by":"crossref","unstructured":"Peschke E, Wolgast S, Bazwinsky I, P\u00f6nicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res. 2008;45:439\u201348.10.1111\/j.1600-079X.2008.00612.x18624957","DOI":"10.1111\/j.1600-079X.2008.00612.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_043_w2aab3b7b2b1b6b1ab1b7c43Aa","doi-asserted-by":"crossref","unstructured":"Owino S, Contreras-Alcantara S, Baba K, Tosini G. Melatonin signaling controls the daily rhythm in blood glucose levels independent of peripheral clocks. PLoS One. 2016;11:1\u201316.","DOI":"10.1371\/journal.pone.0148214"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_044_w2aab3b7b2b1b6b1ab1b7c44Aa","doi-asserted-by":"crossref","unstructured":"Lima FB, Machado UF, Bartol I, Seraphim PM, Sumida DH, Moraes SM, et al. Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol Metab. 2017;275:E934\u201341.","DOI":"10.1152\/ajpendo.1998.275.6.E934"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_045_w2aab3b7b2b1b6b1ab1b7c45Aa","doi-asserted-by":"crossref","unstructured":"Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1\u201316.10.1111\/j.1600-079X.2011.00916.x21752095","DOI":"10.1111\/j.1600-079X.2011.00916.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_046_w2aab3b7b2b1b6b1ab1b7c46Aa","doi-asserted-by":"crossref","unstructured":"Kdziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, Kornatowski T, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333\u20137.10.1111\/j.1600-079X.2009.00666.x19317795","DOI":"10.1111\/j.1600-079X.2009.00666.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_047_w2aab3b7b2b1b6b1ab1b7c47Aa","doi-asserted-by":"crossref","unstructured":"Mayo JC, Sainz RM, Antol\u00edn I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci. 2002;59:1706\u201313.10.1007\/PL0001249812475181","DOI":"10.1007\/PL00012498"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_048_w2aab3b7b2b1b6b1ab1b7c48Aa","doi-asserted-by":"crossref","unstructured":"Hadjzadeh MA, Alikhani V, Hosseinian S, Zarei B, Keshavarzi Z. The effect of melatonin against gastric oxidative stress and dyslipidemia in streptozotocin-induced diabetic rats. Acta Endocrinol (Buchar). 2018;14:453\u20138.3114929610.4183\/aeb.2018.453","DOI":"10.4183\/aeb.2018.453"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_049_w2aab3b7b2b1b6b1ab1b7c49Aa","unstructured":"Luhinich N, Gerush I. Effects of 7-day melatonin introduction on the hydrogen sulfide production and glutathione system in the liver of alloxan induced diabetic rats. Georg Med News. 2019;289:135\u20139."},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_050_w2aab3b7b2b1b6b1ab1b7c50Aa","doi-asserted-by":"crossref","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058\u201370.10.1161\/CIRCRESAHA.110.22354521030723","DOI":"10.1161\/CIRCRESAHA.110.223545"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_051_w2aab3b7b2b1b6b1ab1b7c51Aa","doi-asserted-by":"crossref","unstructured":"Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813\u201320.10.1038\/414813a11742414","DOI":"10.1038\/414813a"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_052_w2aab3b7b2b1b6b1ab1b7c52Aa","doi-asserted-by":"crossref","unstructured":"Zephy D, Ahmad J. Type 2 diabetes mellitus: role of melatonin and oxidative stress. Diabetes Metab Syndr. 2015;9:127\u201331.10.1016\/j.dsx.2014.09.01825450812","DOI":"10.1016\/j.dsx.2014.09.018"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_053_w2aab3b7b2b1b6b1ab1b7c53Aa","doi-asserted-by":"crossref","unstructured":"Wan XD, Li SQ, Xi SM, Wang JF, Guo YC, Wang XM. Long-term melatonin administration improves glucose homeostasis and insulin resistance state in high-fat diet fed rats. Cent Eur J Biol. 2013;8:958\u201367.","DOI":"10.2478\/s11535-013-0211-z"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_054_w2aab3b7b2b1b6b1ab1b7c54Aa","doi-asserted-by":"crossref","unstructured":"Lo CC, Lin SH, Chang JS, Chien YW. Effects of melatonin on glucose homeostasis, antioxidant ability, and adipokine secretion in ICR mice with NA\/STZ-induced hyperglycemia. Nutrients. 2017;9:1187\u2013200.10.3390\/nu9111187","DOI":"10.3390\/nu9111187"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_055_w2aab3b7b2b1b6b1ab1b7c55Aa","doi-asserted-by":"crossref","unstructured":"Rybka J, K\u0119dziora-kornatowska K, Kupczyk D, Muszalik M, Kornatowski M, K\u0119dziora J. Antioxidant effect of immediate- versus sustained-release melatonin in type 2 diabetes mellitus and healthy controls. Drug Deliv. 2016;23:814.24865293","DOI":"10.3109\/10717544.2014.917343"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_056_w2aab3b7b2b1b6b1ab1b7c56Aa","doi-asserted-by":"crossref","unstructured":"Bonnefond A, Froguel P. The case for too little melatonin signalling in increased diabetes risk. Diabetologia. 2017;60:823\u20135.2831494410.1007\/s00125-017-4255-x","DOI":"10.1007\/s00125-017-4255-x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_057_w2aab3b7b2b1b6b1ab1b7c57Aa","doi-asserted-by":"crossref","unstructured":"Amaral FG, Turati AO, Barone M, Scialfa JH, Do Carmo Buonfiglio D, Peres R, et al. Melatonin synthesis impairment as a new deleterious outcome of diabetes-derived hyperglycemia. J Pineal Res. 2014;57:67\u201379.10.1111\/jpi.1214424819547","DOI":"10.1111\/jpi.12144"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_058_w2aab3b7b2b1b6b1ab1b7c58Aa","doi-asserted-by":"crossref","unstructured":"Sharma S, Singh H, Ahmad N, Mishra P, Tiwari A. The role of melatonin in diabetes: therapeutic implications. Arch Endocrinol Metab. 2015;59:391\u20139.10.1590\/2359-399700000009826331226","DOI":"10.1590\/2359-3997000000098"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_059_w2aab3b7b2b1b6b1ab1b7c59Aa","doi-asserted-by":"crossref","unstructured":"Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150:5311\u20137.10.1210\/en.2009-042519819971","DOI":"10.1210\/en.2009-0425"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_060_w2aab3b7b2b1b6b1ab1b7c60Aa","doi-asserted-by":"crossref","unstructured":"de Oliveira AC, Andreotti S, Farias Tda S, Torres-Leal FL, De Proen\u00e7a AR, Campa\u00f1a AB, et al. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZ-induced diabetic rats are improved by long-term melatonin treatment. Endocrinology. 2012;153:2178\u201388.10.1210\/en.2011-167522374967","DOI":"10.1210\/en.2011-1675"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_061_w2aab3b7b2b1b6b1ab1b7c61Aa","doi-asserted-by":"crossref","unstructured":"de Oliveira AC, Andreotti S, Sertie RA, Campana AB, de Proen\u00e7a AR, Vasconcelos RP, et al. Combined treatment with melatonin and insulin improves glycemic control, white adipose tissue metabolism and reproductive axis of diabetic male rats. Life Sci. 2018;199:158\u201366.10.1016\/j.lfs.2018.02.04029501522","DOI":"10.1016\/j.lfs.2018.02.040"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_062_w2aab3b7b2b1b6b1ab1b7c62Aa","doi-asserted-by":"crossref","unstructured":"Bundhun PK, Bhurtu A, Yuan J. Impact of type 2 diabetes mellitus on the long-term mortality in patients who were treated by coronary artery bypass surgery. Med (Baltimore). 2017;96:e7022.","DOI":"10.1097\/MD.0000000000007022"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_063_w2aab3b7b2b1b6b1ab1b7c63Aa","doi-asserted-by":"crossref","unstructured":"Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:2568\u20139.10.2337\/diacare.27.10.256815451946","DOI":"10.2337\/diacare.27.10.2568"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_064_w2aab3b7b2b1b6b1ab1b7c64Aa","doi-asserted-by":"crossref","unstructured":"Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38:191\u20136.2927591910.1016\/j.clnu.2017.12.004","DOI":"10.1016\/j.clnu.2017.12.004"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_065_w2aab3b7b2b1b6b1ab1b7c65Aa","doi-asserted-by":"crossref","unstructured":"Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31\u20139.2018002610.1007\/s11154-010-9131-7","DOI":"10.1007\/s11154-010-9131-7"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_066_w2aab3b7b2b1b6b1ab1b7c66Aa","doi-asserted-by":"crossref","unstructured":"Zhou H, Yue Y, Wang J, Ma Q, Chen Y. Melatonin therapy for diabetic cardiomyopathy: a mechanism involving Syk-mitochondrial complex I-SERCA pathway. Cell Signal. 2018;47:88\u2013100.10.1016\/j.cellsig.2018.03.01229601906","DOI":"10.1016\/j.cellsig.2018.03.012"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_067_w2aab3b7b2b1b6b1ab1b7c67Aa","doi-asserted-by":"crossref","unstructured":"Amin AH, El-Missiry MA, Othman Al. Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes induced apoptosis. Eur J Pharmacol. 2014;747(December):166\u201373.25510232","DOI":"10.1016\/j.ejphar.2014.12.002"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_068_w2aab3b7b2b1b6b1ab1b7c68Aa","doi-asserted-by":"crossref","unstructured":"Ouyang C, You J, Xie Z. The interplay between autophagy and apoptosis in the diabetic heart. J Mol Cell Cardiol. 2014;71:71\u201380.2451307910.1016\/j.yjmcc.2013.10.014","DOI":"10.1016\/j.yjmcc.2013.10.014"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_069_w2aab3b7b2b1b6b1ab1b7c69Aa","doi-asserted-by":"crossref","unstructured":"Xiong FY, Tang ST, Su H, Tang HQ, Jiang P, Zhou Q, et al. Melatonin ameliorates myocardial apoptosis by suppressing endoplasmic reticulum stress in rats with long \u2013 term diabetic cardiomyopathy. Mol Med Rep. 2018;17:374\u201381.","DOI":"10.3892\/mmr.2017.7841"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_070_w2aab3b7b2b1b6b1ab1b7c70Aa","doi-asserted-by":"crossref","unstructured":"Wang W, Wang W, Azadzoi KM, Dai P, Wang Q, Sun J, et al. Alu RNA accumulation in hyperglycemia augments oxidative stress and impairs eNOS and SOD2 expression in endothelial cells. Mol Cell Endocrinol. 2016;426:91\u2013100.10.1016\/j.mce.2016.02.00826891959","DOI":"10.1016\/j.mce.2016.02.008"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_071_w2aab3b7b2b1b6b1ab1b7c71Aa","doi-asserted-by":"crossref","unstructured":"Li C, Lv L, Li H, Yu D. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol. 2012;11:1\u201310.","DOI":"10.1186\/1475-2840-11-73"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_072_w2aab3b7b2b1b6b1ab1b7c72Aa","doi-asserted-by":"crossref","unstructured":"Salmanoglu DS, Gurpinar T, Vural K, Ekerbicer N, Dar\u0131verenli E, Var A. Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in type 2 diabetic rats. Redox Biol. 2016;8:199\u2013204.2680348110.1016\/j.redox.2015.11.007","DOI":"10.1016\/j.redox.2015.11.007"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_073_w2aab3b7b2b1b6b1ab1b7c73Aa","doi-asserted-by":"crossref","unstructured":"Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403\u201319.2627223510.1111\/jpi.12267","DOI":"10.1111\/jpi.12267"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_074_w2aab3b7b2b1b6b1ab1b7c74Aa","doi-asserted-by":"crossref","unstructured":"Kandemir YB, Tosun V, G\u00fcntekin \u00dc. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway. Adv Clin Exp Med. 2019;28:1171\u20137.3084367210.17219\/acem\/103799","DOI":"10.17219\/acem\/103799"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_075_w2aab3b7b2b1b6b1ab1b7c75Aa","doi-asserted-by":"crossref","unstructured":"Behram Kandemir Y, Guntekin \u00dc, Tosun V, Korucuk N, Bozdemir MN. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Cell Mol Biol (Noisy-le-grand). 2018;64:47\u201352.10.14715\/cmb\/2018.64.14.830511620","DOI":"10.14715\/cmb\/2018.64.14.8"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_076_w2aab3b7b2b1b6b1ab1b7c76Aa","doi-asserted-by":"crossref","unstructured":"Dal B, Francisco S, Parente EB, Carolina A, Campos N, Cury AN, et al. Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography. PLoS One 2017;12:1\u20139.","DOI":"10.1371\/journal.pone.0171733"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_077_w2aab3b7b2b1b6b1ab1b7c77Aa","doi-asserted-by":"crossref","unstructured":"Michaelson J, Hariharan V, Huang H. Hyperglycemic and hyperlipidemic conditionsalter cardiac cell biomechanical properties. Biophys J. 2014;106:2322\u20139.10.1016\/j.bpj.2014.04.04024896111","DOI":"10.1016\/j.bpj.2014.04.040"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_078_w2aab3b7b2b1b6b1ab1b7c78Aa","doi-asserted-by":"crossref","unstructured":"Kwong B, Tan H, Hong C, Natesan P. Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin-induced diabetic rats. Life Sci. 2005;76:2827\u201339.10.1016\/j.lfs.2004.10.05115808883","DOI":"10.1016\/j.lfs.2004.10.051"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_079_w2aab3b7b2b1b6b1ab1b7c79Aa","doi-asserted-by":"crossref","unstructured":"Agil A, Navarro-Alarcon M, Ruiz R, Abuhamadah S, El-Mir MY, Vazquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res. 2011;50:207\u201312.21087312","DOI":"10.1111\/j.1600-079X.2010.00830.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_080_w2aab3b7b2b1b6b1ab1b7c80Aa","doi-asserted-by":"crossref","unstructured":"Tengattini S, Russel J, Tan D, Pilar M, Rodella LF. Cardiovascular diseases: protective effects of melatonin. J Pineal Res. 2008;44:16\u201325.18078444","DOI":"10.1111\/j.1600-079X.2007.00518.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_081_w2aab3b7b2b1b6b1ab1b7c81Aa","doi-asserted-by":"crossref","unstructured":"Mehmeti I, Lenzen S, Lortz S. Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status. Mol Cell Endocrinol. 2011;332:88\u201396.2093305410.1016\/j.mce.2010.09.017","DOI":"10.1016\/j.mce.2010.09.017"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_082_w2aab3b7b2b1b6b1ab1b7c82Aa","doi-asserted-by":"crossref","unstructured":"Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. Neuroscience. 2005;135:879\u201386.10.1016\/j.neuroscience.2005.05.04816213988","DOI":"10.1016\/j.neuroscience.2005.05.048"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_083_w2aab3b7b2b1b6b1ab1b7c83Aa","doi-asserted-by":"crossref","unstructured":"Yu L, Liang H, Lu Z, Zhao G, Zhai M, Yang Y, et al. Membrane receptor-dependent Notch1\/Hes1 activation by melatonin protects against myocardial ischemia-reperfusion injury: in vivo and in vitro studies. J Pineal Res. 2015;59:420\u201333.2630896310.1111\/jpi.12272","DOI":"10.1111\/jpi.12272"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_084_w2aab3b7b2b1b6b1ab1b7c84Aa","doi-asserted-by":"crossref","unstructured":"Yu L, Liang H, Dong X, Zhao G, Jin Z, Zhai M, et al. Reduced silent information regulator 1 signaling exacerbates myocardial ischemia-reperfusion injury in type 2 diabetic rats and the protective effect of melatonin. J Pineal Res. 2015;59:376\u201390.2632719710.1111\/jpi.12269","DOI":"10.1111\/jpi.12269"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_085_w2aab3b7b2b1b6b1ab1b7c85Aa","doi-asserted-by":"crossref","unstructured":"Yu L, Di W, Dong X, Li Z, Zhang Y, Xue X, et al. Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation. BBA \u2013 Mol Basis Dis. 2018;1864:563\u201378.10.1016\/j.bbadis.2017.11.023","DOI":"10.1016\/j.bbadis.2017.11.023"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_086_w2aab3b7b2b1b6b1ab1b7c86Aa","doi-asserted-by":"crossref","unstructured":"Tang S, Su H, Zhang Q, Tang H, Wang C, Zhou Q, et al. Melatonin attenuates aortic endothelial permeability and arteriosclerosis in streptozotocin-induced diabetic rats: possible role of MLCK- and MLCP-dependent MLC phosphorylation. J Cardiovasc Pharmacol Ther. 2016;21:82\u201392.2594484410.1177\/1074248415583090","DOI":"10.1177\/1074248415583090"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_087_w2aab3b7b2b1b6b1ab1b7c87Aa","doi-asserted-by":"crossref","unstructured":"Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1\u03b1 pathway. J Pineal Res. 2018;65:e12491.29575122","DOI":"10.1111\/jpi.12491"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_088_w2aab3b7b2b1b6b1ab1b7c88Aa","doi-asserted-by":"crossref","unstructured":"Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, et al. NF-kappa B-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 2010;85:473\u201383.10.1093\/cvr\/cvp305","DOI":"10.1093\/cvr\/cvp305"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_089_w2aab3b7b2b1b6b1ab1b7c89Aa","doi-asserted-by":"crossref","unstructured":"Verma SK, Garikipati VN, Kishore R. Mitochondrial dysfunction and its impact on diabetic heart. Biochim Biophys Acta Mol Basis Dis. 2017;1863:1098\u2013105.2759369510.1016\/j.bbadis.2016.08.021","DOI":"10.1016\/j.bbadis.2016.08.021"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_090_w2aab3b7b2b1b6b1ab1b7c90Aa","doi-asserted-by":"crossref","unstructured":"Wang S, Zhao Z, Feng X, Cheng Z, Xiong Z, Wang T, et al. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. J Cell Mol Med. 2018;22:5132\u201344.10.1111\/jcmm.1380230063115","DOI":"10.1111\/jcmm.13802"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_091_w2aab3b7b2b1b6b1ab1b7c91Aa","doi-asserted-by":"crossref","unstructured":"Hu J, Wang T, Man W, Yin T, Guo W, Gao E, et al. Melatonin protects against diabetic cardiomyopathy through Mst1\/Sirt3 signaling. J Pineal Res. 2017;63:1\u201313.","DOI":"10.1111\/jpi.12418"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_092_w2aab3b7b2b1b6b1ab1b7c92Aa","doi-asserted-by":"crossref","unstructured":"Rangasamy S, Mcguire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52\u201329.2234611510.4103\/0974-9233.92116","DOI":"10.4103\/0974-9233.92116"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_093_w2aab3b7b2b1b6b1ab1b7c93Aa","doi-asserted-by":"crossref","unstructured":"Mitsuhashi J, Morikawa S, Shimizu K, Ezaki T, Yasuda Y. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res. 2013;106:64\u201373.2317855110.1016\/j.exer.2012.11.001","DOI":"10.1016\/j.exer.2012.11.001"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_094_w2aab3b7b2b1b6b1ab1b7c94Aa","unstructured":"Masoud RE. Prevention of diabetic retinopathy by melatonin in rats with STZ induced diabetes mellitus. Int J Sci Res. 2017;6:843\u20137."},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_095_w2aab3b7b2b1b6b1ab1b7c95Aa","doi-asserted-by":"crossref","unstructured":"Gundogan FC, Yolcu U, Akay F, Ilhan A, Ozge G, Uzun S. Diabetic macular edema. Pak J Med Sci. 2016;32:505\u201310.27182271","DOI":"10.12669\/pjms.322.8496"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_096_w2aab3b7b2b1b6b1ab1b7c96Aa","doi-asserted-by":"crossref","unstructured":"Crooke A, Basilio FH, Jes\u00fas C. The role and therapeutic potential of melatonin in age related ocular diseases. J Pineal Res. 2017;63:1\u201325.","DOI":"10.1111\/jpi.12430"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_097_w2aab3b7b2b1b6b1ab1b7c97Aa","doi-asserted-by":"crossref","unstructured":"Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic. Diabetes Care. 2003;26:2653\u201364.12941734","DOI":"10.2337\/diacare.26.9.2653"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_098_w2aab3b7b2b1b6b1ab1b7c98Aa","doi-asserted-by":"crossref","unstructured":"Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20\u201333.2920314810.1016\/j.lfs.2017.12.001","DOI":"10.1016\/j.lfs.2017.12.001"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_099_w2aab3b7b2b1b6b1ab1b7c99Aa","doi-asserted-by":"crossref","unstructured":"Santos JM, Tewari S, Kowluru RA. A compensatory mechanism protects retinal mitochondria from initial insult in diabetic retinopathy. Free Radic Biol Med. 2012;53:1729\u201337.2298204610.1016\/j.freeradbiomed.2012.08.588","DOI":"10.1016\/j.freeradbiomed.2012.08.588"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_100_w2aab3b7b2b1b6b1ab1b7d100Aa","doi-asserted-by":"crossref","unstructured":"Djordjevic B, Cvetkovic T, Jevtovic T, Despotovic M, Zivanovic S, Basic J, et al. Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin\/nicotinamide induced pre-diabetes. Eur J Pharmacol. 2018;833:290\u20137.10.1016\/j.ejphar.2018.06.01129890158","DOI":"10.1016\/j.ejphar.2018.06.011"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_101_w2aab3b7b2b1b6b1ab1b7d101Aa","doi-asserted-by":"crossref","unstructured":"Ozdemir G, Erg\u00fcn Y, Bakari\u015f S, K\u0131l\u0131n\u00e7 M, Durdu H, Ganiyusufo\u011flu E. Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats. Eye (Lond). 2014;28:1020\u20137.2492444110.1038\/eye.2014.127","DOI":"10.1038\/eye.2014.127"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_102_w2aab3b7b2b1b6b1ab1b7d102Aa","doi-asserted-by":"crossref","unstructured":"Salido EM, Zaval\u00eda N, Schreier L, De Laurentiis A, Rettori V, Chianelli M, et al. Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia. Exp Neurol. 2012;236:151\u201360.10.1016\/j.expneurol.2012.04.010","DOI":"10.1016\/j.expneurol.2012.04.010"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_103_w2aab3b7b2b1b6b1ab1b7d103Aa","doi-asserted-by":"crossref","unstructured":"Yang JH, Kwak HW, Kim TG, Han J, Moon SW, Yu SY. Retinal neurodegeneration in type II diabetic Otsuka Long-Evans Tokushima fatty rats. IOVS 2013;54:3844\u201351.","DOI":"10.1167\/iovs.12-11309"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_104_w2aab3b7b2b1b6b1ab1b7d104Aa","doi-asserted-by":"crossref","unstructured":"Ellis EA, Guberski DL, Hutson B, Grant MB. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ\/OR rat. Nitric Oxide Biol Chem. 2002;6:295\u2013304.10.1006\/niox.2001.0419","DOI":"10.1006\/niox.2001.0419"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_105_w2aab3b7b2b1b6b1ab1b7d105Aa","doi-asserted-by":"crossref","unstructured":"Kumar A, Chen S, Kadiiska MB, Hong J, Zielonka J, Kalyanaraman B, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med. 2014;73:51\u20139.2474661710.1016\/j.freeradbiomed.2014.04.014","DOI":"10.1016\/j.freeradbiomed.2014.04.014"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_106_w2aab3b7b2b1b6b1ab1b7d106Aa","doi-asserted-by":"crossref","unstructured":"Al-shabrawey M, Bartoli M, El-remessy AB, Ma G, Matragoon S, Lemtalsi T, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3231\u20138.1837857010.1167\/iovs.08-1754","DOI":"10.1167\/iovs.08-1754"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_107_w2aab3b7b2b1b6b1ab1b7d107Aa","unstructured":"Kumawat M, Kharb S, Singh V, Singh N, Singh S, Nada M. Plasma malondialdehyde (MDA) and anti-oxidant status in diabetic retinopathy. J Indian Med Assoc. 2014;112:29\u201332.25935946"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_108_w2aab3b7b2b1b6b1ab1b7d108Aa","doi-asserted-by":"crossref","unstructured":"Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1\u201329.10.1016\/S1350-9462(02)00043-512597922","DOI":"10.1016\/S1350-9462(02)00043-5"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_109_w2aab3b7b2b1b6b1ab1b7d109Aa","doi-asserted-by":"crossref","unstructured":"Jiang T, Chang Q, Zhao Z, Yan S, Wang L, Cai J, et al. Melatonin-mediated cytoprotection against hyperglycemic injury in Muller cells. PLoS One 2012;7:1\u20138.","DOI":"10.1371\/journal.pone.0050661"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_110_w2aab3b7b2b1b6b1ab1b7d110Aa","doi-asserted-by":"crossref","unstructured":"Jiang T, Chang Q, Cai J, Fan J, Zhang X, Xu G. Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy. Oxid Med Cell Longev. 2016;2016:3528274.27143993","DOI":"10.1155\/2016\/3528274"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_111_w2aab3b7b2b1b6b1ab1b7d111Aa","doi-asserted-by":"crossref","unstructured":"Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30:1\u201312.10.1016\/j.mam.2008.08.00618796312","DOI":"10.1016\/j.mam.2008.08.006"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_112_w2aab3b7b2b1b6b1ab1b7d112Aa","unstructured":"Xie M, Hu A, Luo Y, Sun W, Hu X, Tang S. Interleukin-4 and melatonin ameliorate high glucose and interleukin-1\u03b2 stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis. 2014;20:921\u20138.24991184"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_113_w2aab3b7b2b1b6b1ab1b7d113Aa","doi-asserted-by":"crossref","unstructured":"Salido EM, Bordone M, Laurentiis A, Chianelli M, Sarmiento MI, Dorfman D, et al. Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res. 2013;54:179\u201389.10.1111\/jpi.12008","DOI":"10.1111\/jpi.12008"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_114_w2aab3b7b2b1b6b1ab1b7d114Aa","doi-asserted-by":"crossref","unstructured":"Gul M, Emre S, Esrefoglu M, Vard\u0131 N. Protective effects of melatonin and aminoguanidine on the cornea in streptozotocin-induced diabetic rats. Cornea. 2008;27:795\u2013801.10.1097\/ICO.0b013e318169d67c18650666","DOI":"10.1097\/ICO.0b013e318169d67c"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_115_w2aab3b7b2b1b6b1ab1b7d115Aa","doi-asserted-by":"crossref","unstructured":"Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21\u201335.10.1016\/j.phrs.2013.12.00524373831","DOI":"10.1016\/j.phrs.2013.12.005"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_116_w2aab3b7b2b1b6b1ab1b7d116Aa","doi-asserted-by":"crossref","unstructured":"Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28:8\u201314.10.1002\/dmrr.223922271716","DOI":"10.1002\/dmrr.2239"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_117_w2aab3b7b2b1b6b1ab1b7d117Aa","doi-asserted-by":"crossref","unstructured":"Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629\u201338.10.1002\/dmrr.122521695762","DOI":"10.1002\/dmrr.1225"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_118_w2aab3b7b2b1b6b1ab1b7d118Aa","doi-asserted-by":"crossref","unstructured":"Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285\u201393.10.2337\/dc10-130320876709","DOI":"10.2337\/dc10-1303"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_119_w2aab3b7b2b1b6b1ab1b7d119Aa","doi-asserted-by":"crossref","unstructured":"Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521\u201334.2260866610.1016\/S1474-4422(12)70065-0","DOI":"10.1016\/S1474-4422(12)70065-0"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_120_w2aab3b7b2b1b6b1ab1b7d120Aa","doi-asserted-by":"crossref","unstructured":"Feldman EL, Nave K, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296\u2013313.10.1016\/j.neuron.2017.02.00528334605","DOI":"10.1016\/j.neuron.2017.02.005"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_121_w2aab3b7b2b1b6b1ab1b7d121Aa","doi-asserted-by":"crossref","unstructured":"Zenker J, Ziegler D, Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36:439\u201349.10.1016\/j.tins.2013.04.00823725712","DOI":"10.1016\/j.tins.2013.04.008"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_122_w2aab3b7b2b1b6b1ab1b7d122Aa","doi-asserted-by":"crossref","unstructured":"Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol. 2007;576:34\u201342.10.1016\/j.ejphar.2007.08.00117822693","DOI":"10.1016\/j.ejphar.2007.08.001"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_123_w2aab3b7b2b1b6b1ab1b7d123Aa","doi-asserted-by":"crossref","unstructured":"Jangra A, Datusalia AK, Khandwe S, Sharma SS. Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: implication of oxidative stress\u2013PARP pathway. Phamarcol Biochem Behav. 2013;114\u2013115:43\u201351.","DOI":"10.1016\/j.pbb.2013.10.021"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_124_w2aab3b7b2b1b6b1ab1b7d124Aa","doi-asserted-by":"crossref","unstructured":"Baydas G, Reiter RJ, Yasar A, Tuzcu M, Akdemir I, Nedzvetskii VS. Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. Free Radic Biol Med. 2003;35:797\u2013804.10.1016\/S0891-5849(03)00408-814583344","DOI":"10.1016\/S0891-5849(03)00408-8"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_125_w2aab3b7b2b1b6b1ab1b7d125Aa","doi-asserted-by":"crossref","unstructured":"Metwally MM, Ebraheim LL, Galal AA. Potential therapeutic role of melatonin on STZ-induced diabetic central neuropathy: a biochemical, histopathological, immunohistochemical and ultrastructural study. Acta Histochem. 2018;120:828\u201336.10.1016\/j.acthis.2018.09.00830268437","DOI":"10.1016\/j.acthis.2018.09.008"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_126_w2aab3b7b2b1b6b1ab1b7d126Aa","doi-asserted-by":"crossref","unstructured":"Leeboonngam T, Pramong R, Sae-ung K, Govitrapong P, Phansuwan-Pujito P. Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats. J Pineal Res. 2018;64:1\u201319.","DOI":"10.1111\/jpi.12456"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_127_w2aab3b7b2b1b6b1ab1b7d127Aa","doi-asserted-by":"crossref","unstructured":"Ali T, Rehman SU, Shah FA, Kim MO. Acute dose of melatonin via Nrf2 dependently prevents acute ethanol-induced neurotoxicity in the developing rodent brain. J Neuroinflammation. 2018;15:119\u201338.10.1186\/s12974-018-1157-x29679979","DOI":"10.1186\/s12974-018-1157-x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_128_w2aab3b7b2b1b6b1ab1b7d128Aa","doi-asserted-by":"crossref","unstructured":"Negi G, Kumar A, Joshi RP, Sharma SS. Biochemical and biophysical research communications oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem Biophys Res Commun. 2011;408:1\u20135.10.1016\/j.bbrc.2011.03.08721439933","DOI":"10.1016\/j.bbrc.2011.03.087"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_129_w2aab3b7b2b1b6b1ab1b7d129Aa","doi-asserted-by":"crossref","unstructured":"Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-\u03baB and Nrf2 cascades. J Pineal Res. 2011;50:124\u201331.21062351","DOI":"10.1111\/j.1600-079X.2010.00821.x"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_130_w2aab3b7b2b1b6b1ab1b7d130Aa","doi-asserted-by":"crossref","unstructured":"Kireev RA, Cuesta S, Vara E, Tresguerres JA. Effect of growth hormone and melatonin on the brain: from molecular mechanisms to structural changes. Horm Mol Bio Clin Investig. 2011;7:337\u201350.","DOI":"10.1515\/HMBCI.2011.115"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_131_w2aab3b7b2b1b6b1ab1b7d131Aa","doi-asserted-by":"crossref","unstructured":"Onphachanch X, Lee HJ, Lim JR, Jung YH, Kim JS, Chae CW, et al. Enhancement of high glucose-induced PINK1 expression by melatonin stimulates neuronal cell survival: involvement of MT2\/Akt\/NF-\u03baB pathway. J Pineal Res. 2017;63:1\u201317.","DOI":"10.1111\/jpi.12427"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_132_w2aab3b7b2b1b6b1ab1b7d132Aa","doi-asserted-by":"crossref","unstructured":"Tiong YL, Ng KY, Koh RY, Ponnudurai G, Chye SM. Melatonin prevents oxidative stress-induced mitochondrial dysfunction and apoptosis in high glucose-treated schwann cells via upregulation of Bcl2, NF-\u03baB, mTOR, Wnt signalling pathways. Antioxidants (Basel). 2019;8: 1\u2013 15.","DOI":"10.3390\/antiox8070198"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_133_w2aab3b7b2b1b6b1ab1b7d133Aa","doi-asserted-by":"crossref","unstructured":"Song J, Kim OY. Melatonin modulates neuronal cell death induced by endoplasmic reticulum stress under insulin resistance condition. Nutrients. 2017;9:593\u2013608.10.3390\/nu9060593","DOI":"10.3390\/nu9060593"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_134_w2aab3b7b2b1b6b1ab1b7d134Aa","doi-asserted-by":"crossref","unstructured":"Zangiabadi N, Sheibani V, Asadi-Shekaari M, Shabani M, Jafari M, Asadi AR, et al. Effects of melatonin in prevention of neuropathy in STZ-induced diabetic rats. Am J Pharmacol Toxicol. 2011;6:59\u201367.10.3844\/ajptsp.2011.59.67","DOI":"10.3844\/ajptsp.2011.59.67"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_135_w2aab3b7b2b1b6b1ab1b7d135Aa","doi-asserted-by":"crossref","unstructured":"Gokce S, Dincer M, Yaraneri H. Electrophysiological and theoretical analysis of melatonin in peripheral nerve crush injury. J Neurosci Methods. 2010;191:277\u201382.10.1016\/j.jneumeth.2010.07.00820637233","DOI":"10.1016\/j.jneumeth.2010.07.008"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_136_w2aab3b7b2b1b6b1ab1b7d136Aa","doi-asserted-by":"crossref","unstructured":"Seyit DA, Degirmenci E, Oguzhanoglu A. Evaluation of electrophysiological effects of melatonin and alpha lipoic acid in rats with streptozotocine induced diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2016;124:300\u20136.10.1055\/s-0042-10375027219687","DOI":"10.1055\/s-0042-103750"},{"key":"2025121207171211691_j_hmbci-2019-0036_ref_137_w2aab3b7b2b1b6b1ab1b7d137Aa","doi-asserted-by":"crossref","unstructured":"Chang HM, Liu CH, Hsu WM, Chen LY, Wang HP, Wu TH, et al. Proliferative effects of melatonin on Schwann cells\u202f: implication for nerve regeneration following peripheral nerve injury. J Pineal Res. 2014;56:322\u201332.2449929610.1111\/jpi.12125","DOI":"10.1111\/jpi.12125"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2019.40.issue-1\/hmbci-2019-0036\/hmbci-2019-0036.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0036\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:07:50Z","timestamp":1765526870000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2019-0036\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":137,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2019,10,25]]}},"alternative-id":["10.1515\/hmbci-2019-0036"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2019-0036","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"value":"1868-1891","type":"electronic"},{"value":"1868-1883","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"article-number":"20190036"}}